titan bpc 157 Peptides Archives INJECTABLE PEPTIDES - Titan Medical

Simple options

The Phase 2 trial enrolled participants with obesity and evaluated multiple dose levels over 48 weeks: 1 mg dose: 8.7% average body weight reduction 4 mg dose (escalated from 2 mg): 17.1% average body weight reduction 8 mg dose (escalated from 2 mg): 22.8% average body weight reduction 12 mg dose (escalated from 2 mg): 24.2% average body weight reduction Placebo: 2.1% average body weight reduction Those Phase 2 numbers were striking enough

Every batch ships with full COA documentation including HPLC purity data and MS identity confirmation

Join here.

Cagrilintide - 5mg - Batch - 0126 - Purity Cagrilintide (Cagrilintid) 5 mg Amylin-Analogon